Tolvaptan

Generic Name
Tolvaptan
Brand Names
Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
Drug Type
Small Molecule
Chemical Formula
C26H25ClN2O3
CAS Number
150683-30-0
Unique Ingredient Identifier
1E2497LPNY
Background

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

Indication

Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.

Associated Conditions
Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
Associated Therapies
-
Clinical Trials
Related News

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Phase 4
Recruiting
Conditions
Takayasu Arteritis
Interventions
Drug: Tofacitinib
Drug: Methotrexate
First Posted Date
2021-11-01
Last Posted Date
2024-10-14
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
76
Registration Number
NCT05102448
Locations
🇨🇳

Lindi Jiang, Shanghai, Shanghai, China

Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

Phase 2
Conditions
Primary Sjögren's Syndrome
Interventions
Drug: Tofacitinib
First Posted Date
2021-10-21
Last Posted Date
2022-03-02
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
10
Registration Number
NCT05087589
Locations
🇨🇳

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China

COVID-19 VaccinE Response in Rheumatology Patients

First Posted Date
2021-10-15
Last Posted Date
2023-11-08
Lead Sponsor
Jeffrey Curtis
Target Recruit Count
1000
Registration Number
NCT05080218
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States

🇺🇸

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

and more 5 locations

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

First Posted Date
2021-09-17
Last Posted Date
2024-03-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
7
Registration Number
NCT05048238
Locations
🇺🇸

University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States

🇺🇸

University of Massachusetts Medical School, Worcester, Massachusetts, United States

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tofacitinib
First Posted Date
2021-08-02
Last Posted Date
2022-10-14
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT04985955
Locations
🇧🇪

Clinical Pharmacology Unit, Merksem, Belgium

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
10
Registration Number
NCT04973033
Locations
🇨🇳

Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai, Shanghai, China

Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA

First Posted Date
2021-06-29
Last Posted Date
2021-07-09
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
66
Registration Number
NCT04944524
Locations
🇨🇳

Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai, Shanghai, China

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

First Posted Date
2021-06-16
Last Posted Date
2023-11-18
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
100
Registration Number
NCT04928066
Locations
🇨🇳

Qilu Hospital, Jinan, Shandong, China

The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

Phase 4
Conditions
Rheumatoid Arthritis
Interventions
Drug: Tofacitinib
First Posted Date
2021-06-15
Last Posted Date
2021-06-15
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
170
Registration Number
NCT04927000
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

First Posted Date
2021-03-15
Last Posted Date
2022-06-22
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
105711
Registration Number
NCT04798287
Locations
🇺🇸

Brigham And Women's Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy